Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.67 |
| ▸ | PIP5K1C | O60331 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | PIP5K1B | O14986 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PIP5K1A | Q99755 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829077 | 0.86 | NPY5R (0.61) | NPY5RMAPT | |
| SCHEMBL6829078 | 0.83 | NPY5R (0.63) | NPY5RMAPK8MAPK10HDAC3HDAC1 | |
| SCHEMBL6823457 | 0.83 | NPY5R (0.62) | NPY5RMAPT | |
| SCHEMBL6823387 | 0.82 | NPY5R (0.61) | NPY5RMAPT | |
| SCHEMBL6826862 | 0.82 | NPY5R (0.61) | NPY5RMAPK8MAPK10MAPK14MAPT | |
| SCHEMBL6824384 | 0.81 | NPY5R (0.59) | NPY5RMAPT | |
| SCHEMBL6829168 | 0.80 | NPY5R (1.00) | NPY5RMAPT | |
| SCHEMBL6826590 | 0.79 | NPY5R (0.60) | NPY5RMAPT | |
| SCHEMBL6823480 | 0.78 | NPY5R (0.56) | NPY5RMAPK8 | |
| SCHEMBL6829107 | 0.77 | NPY5R (0.64) | NPY5RMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1358157-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002051806-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | NPY5R, NPY1R, NPY2R | NPY5R 1/4885PIP5K1C 1343/4885PIK3CA 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.